Granules India Secures Sole First-to-File Status for Narcolepsy Drug Generic
Granules India has secured sole first-to-file (FTF) status for its abbreviated new drug application (ANDA) for sodium oxybate extended-release oral suspension, the generic equivalent of LUMRYZ, used in the US to treat cataplexy and excessive daytime sleepiness in narcolepsy patients. This marks the company's second sole FTF ANDA, following its earlier success with amphetamine extended-release tablets. The designation may grant Granules 180 days of market exclusivity, reflecting its focus on complex generics and regulatory capabilities in the US market.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is positive (75/100). Lens Score 32/100 — low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
- thehindu— balanced framing, positive sentiment
- businessstandard— balanced framing, positive sentiment
- businessstandard— balanced framing, positive sentiment
- businessstandard— balanced framing, positive sentiment
AI Analysis
The articles primarily present a business and regulatory perspective without political framing. They focus on Granules India's achievements in the pharmaceutical sector, highlighting regulatory milestones and market implications. There is no evident political bias, as the coverage centers on corporate developments and industry context rather than political viewpoints or controversies.
The overall tone across the articles is positive, emphasizing Granules India's progress and strategic growth in complex generics. The language highlights milestones and capabilities without exaggeration, maintaining a professional and factual tone. There is no negative or critical sentiment, reflecting a straightforward report on the company's regulatory success.
How 4 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.